Moleculin Biotech Inc. (NASDAQ:MBRX) released updated blinded preliminary outcomes from Part A of its Phase 2/3 MIRACLE trial evaluating Annamycin with cytarabine for relapsed or refractory acute myeloid leukemia. Concurrently, the biopharmaceutical enterprise announced the pricing of a public stock…

Biotechnology firm Tiziana Life Sciences Ltd. (NASDAQ:TLSA) on Friday revealed promising quantitative PET imaging results from the third patient participating in its Phase 2 clinical trial. The ongoing study evaluates the company’s lead candidate, intranasal foralumab, designed as a treatment…

Dominion Energy Inc. (NYSE:D) reported better-than-expected second-quarter results on Friday and reaffirmed its full-year 2026 earnings guidance as electricity demand and data center growth continued to support its outlook. Adjusted earnings were 79 cents per share, topping the analyst consensus…

BioAge Labs Inc. (NASDAQ:BIOA) stock plunged Friday after disappointing Phase 3 cardiovascular trial results from Novo Nordisk A/S (NYSE:NVO) sparked concerns about the potential of NLRP3-targeting therapies. William Blair analyst Andy Hsieh said the results from Novo Nordisk’s ZEUS trial…